Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II study of sintilimab + nab-paclitaxel + S-1 as first-line treatment for advanced gastric or gastroesophageal junction adenocarcinoma
ChiCTR2400080326Phase 2Not yet recruiting
- Sponsor
- Changzhou Cancer Hospital of Soochow University
- Start
- Jan 2024
- Modality
- Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of sintilimab, paclitaxel and tegafur in gastric adenocarcinoma and gastroesophageal junction adenocarcinoma, sponsored by Changzhou Cancer Hospital of Soochow University. Primary endpoints: Progression-free survival and Objective response rate. Planned start Jan 2024; status: not yet recruiting.
02
Drugs
sintilimabpaclitaxeltegafur
03
Conditions
gastric adenocarcinomagastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on ChiCTR2400080326.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400080326.